

DAFTAR PUSTAKA

- Akinjogunla, O.J., Odeyemi, A.T., Udofia, E.-A.S., Adefiranye, O.O., Yah, C.S., Ehinmore, I., *et al.* (2023). *Enterobacteriaceae* isolates from clinical and household tap water samples: antibiotic resistance, screening for extended-spectrum, metallo- and ampC-beta-lactamases, and detection of blaTEM, blaSHV and blaCTX-M in Uyo, Nigeria. *Germs* 13 : 50–59.
- Anonim (2025). CLSI M100 Performance Standards for Antimicrobial Susceptibility Testing, 35th ed, 1. Clinical and Laboratory Standard Institute, Pennsylvania, hal.1-396.
- Anonim (2024). Laporan Program Pengendalian Resistensi Antimikroba (PPRA) Tahun 2024 RSUP Dr. Sardjito. Komite Pengendalian dan Pencegahan Infeksi (PPI) dan Program Pengendalian Resistensi Antimikroba (PPRA). Yogyakarta, hal.1-53.
- Anonim (2023). Laporan Program Kerja Program Pengendalian Resistensi Antimikroba (PPRA) Tahun 2023 RSUP Dr. Sardjito. Komite Pengendalian dan Pencegahan Infeksi (PPI) dan Program Pengendalian Resistensi Antimikroba (PPRA). Yogyakarta, hal.1-129.
- Anonim (2022). The WHO AWaRe (Access, Watch, Reserve) Antibiotic Book, 1st ed. World Health Organization. Geneva, hal.1-697.
- Anonim (2021). Peraturan Menteri Kesehatan Republik Indonesia No 8 Tahun 2021 Tentang Pedoman Penggunaan Antibiotik. Jakarta, hal 1-98.
- Anonim (2019). VITEK® 2 GN, in: *Package Insert VITEK® 2 GN*. bioMerieux, Inc., North Carolina, hal. 1–24.
- Anonim (2018). VITEK® 2 AST-GN93, in: *Package Insert VITEK® 2*. bioMerieux, Inc. North Carolina, hal. 1–17.
- Bala, R., Singh, V.A., Gupta, N., & Rakshit, P. (2020). Prevalence, multidrug-resistance and risk factors for AmpC β -lactamases producing *Escherichia coli* from hospitalized patients. *J Infect Dev Ctries* 14 : 1466–1469.
- Barua, T., Shariff, M., & Thukral, S.S. (2013). Detection and Characterization of AmpC B-Lactamases in Indian Clinical Isolates of *Escherichia coli*, *Klebsiella pneumoniae* and *Klebsiella oxytoca*. *Univers J Microbiol Res* 1 : 15–21.
- Basavaraju, M., & Gunashree, B.S. (2023). *Escherichia coli* : An Overview of Main Characteristics, in: Starčić Erjavec, M. (Ed.), *Escherichia Coli - Old and New Insights*. IntechOpen, hal. 1–21.
- Bui, T., Patel, P., V, C., & Preuss, C. (2024). Cephalosporins. Treasure Island Florida : StatPearls Publishing.
- Bush, K., & Bradford, P.A. (2020). Epidemiology of β -Lactamase-Producing Pathogens. *Clin Microbiol Rev* 33 : 1–37.
- Chakkour, M., Hammoud, Z., Farhat, S., El Roz, A., Ezzeddine, Z., & Ghsein, G. (2024). Overview of *Proteus mirabilis* pathogenicity and virulence. Insights into the role of metals. *Front. Microbiol.* 15 : 1–17.
- Chandrasekhar, D., Parambil, J.C., Chinnu, P.B., Mundadan, C.T., & Pattani, D. (2020). Antibiotics: Need for new fences”, a prospective utilization

- evaluation of cephalosporin's and its combination in tertiary care referral hospital. *Clin Epidemiol Glob Health* 8 : 123–127.
- Dadi, N.C.T., Radochová, B., Vargová, J., & Bujdáková, H. (2021). Impact of Healthcare-Associated Infections Connected to Medical Devices—An Update. *Microorganisms* 9 : 1–23.
- Dahlan, M.S. (2010). Besar Sampel Dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan, 3rd ed. Salemba Medika, Jakarta, hal.1-246.
- Datta, P., Gupta, V., Arora, S., Garg, S., & Chander, J. (2014). Epidemiology of Extended-Spectrum β -Lactamase, AmpC, and Carbapenemase Production in *Proteus mirabilis*. *Jpn J Infect Dis* 67 : 44–46.
- Delgado-Valverde, M., Sojo-Dorado, J., Pascual, Á., & Rodríguez-Baño, J. (2013). Clinical management of infections caused by multidrug-resistant *Enterobacteriaceae*. *Ther Adv Infect Dis* 1 : 49–69.
- Dever, L.A., & Dermody, T.S. (1991). Mechanisms of Bacterial Resistance to Antibiotics. *Arch Intern Med* 151 : 886–895.
- Dong, N., Yang, X., Chan, E.W.-C., Zhang, R., & Chen, S. (2022). *Klebsiella* species: Taxonomy, hypervirulence and multidrug resistance. *eBioMedicine* 79 : 1–11.
- Drinkovic, D., Morris, A.J., Dyet, K., Bakker, S., & Heffernan, H. (2015). Plasmid-mediated AmpC beta-lactamase-producing *Escherichia coli* causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials. *N Z Med J* 128 : 50–59.
- Etemadi, S., Ebrahimzadeh Leylabadlo, H., & Ghotaslou, R. (2020). AmpC β -lactamase among *Enterobacteriaceae*: A new insight. *Gene Reports*.
- Girlich, D., Bonnin, R.A., Dortet, L., & Naas, T. (2020). Genetics of Acquired Antibiotic Resistance Genes in *Proteus spp.* *Front. Microbiol.* 11 : 1–21.
- Gupta, G., Tak, V., & Mathur, P. (2014). Detection of AmpC β Lactamases in Gram-negative Bacteria. *J Lab Physicians* 6 : 001–006.
- Hall, B.G., & Barlow, M. (2004). Evolution of the serine β -lactamases: past, present and future. *Drug Resist Updat* 7 : 111–123.
- Harris, P.N.A., & Ferguson, J.K. (2012). Antibiotic therapy for inducible AmpC β -lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? *Int J Antimicrob Agents* 40 : 297–305.
- Helmy, M.M., & Wasfi, R. (2014). Phenotypic and Molecular Characterization of Plasmid Mediated AmpC β -Lactamases among *Escherichia coli* , *Klebsiella spp.*, and *Proteus mirabilis* Isolated from Urinary Tract Infections in Egyptian Hospitals. *Biomed Res Int* 2014 : 1–8.
- Hulley, S.B., Cummings, S.R., Browner, W.S., Grady, D.G., & Newman, T.B. (2007). Designing Clinical Research, 4th ed. Lippincott William & Wilkins. Philadelphia, hal.1-381.
- Inamdar, D.P., & Anuradha, B. (2020). Phenotypic methods for detection of Amp C β lactamases in Gram negative clinical isolates of a tertiary care hospital. *IJMR* 7 : 125–129.
- Jacoby, G.A. (2009). AmpC β -Lactamases. *Clin Microbiol Rev* 22 : 161–182.

- Jameel, N.U.A., Ejaz, H., Zafar, A., & Amin, H. (1969). Multidrug resistant AmpC β -lactamase producing *Escherichia coli* isolated from a paediatric hospital. *Pak J Med Sci* 30 : 1–4.
- Janda, J.M., & Abbott, S.L. (2021). The Changing Face of the Family *Enterobacteriaceae* (Order: “ *Enterobacteriales* ”): New Members, Taxonomic Issues, Geographic Expansion, and New Diseases and Disease Syndromes. *Clin Microbiol Rev* 34 : 1–45.
- Lee, C.-H., Lee, Y.-T., Kung, C.-H., Ku, W.-W., Kuo, S.-C., Chen, T.-L., *et al.* (2015). Risk factors of community-onset urinary tract infections caused by plasmid-mediated AmpC β -lactamase-producing *Enterobacteriaceae*. *J Microbiol Immunol Infect* 48 : 269–275.
- Li, Y.Y., Cassidy, F., Salmon, A., Keating, D., Herra, C.M., & Schaffer, K. (2015). Detection and epidemiology of plasmid-mediated AmpC β -lactamase producing *Escherichia coli* in two Irish tertiary care hospitals. *J Glob Antimicrob Resist* 3 : 242–246.
- Lin, X., & Kück, U. (2022). Cephalosporins as key lead generation beta-lactam antibiotics. *Appl Microbiol Biotechnol* 106 : 8007–8020.
- Luzzaro, F., Brigante, G., D’Andrea, M.M., Pini, B., Giani, T., Mantengoli, E., *et al.* (2009). Spread of multidrug-resistant *Proteus mirabilis* isolates producing an AmpC-type β -lactamase: epidemiology and clinical management. *Int J Antimicrob Agents* 33 : 328–333.
- Mahon, C.R., Lehman, D.C., & Louis, S. (2019). Chapter 12: Antibacterial Mechanism of Action and Bacterial Resistance Mechanism, in: Mahon, C.R & Lehman, D.C (Ed.) *Textbook of Diagnostic Microbiology*. Elsevier Saunders, Missouri, hal. 247–267.
- Mawarti, Y., Dewi, A.D., Wulandari, A., Soetardjo, I.A.E., Muljono, B., Sianipar, O., *et al.* (2024). Pola Mikroba dan Kepekaan Terhadap Antimikroba (Antibiogram) Tahun 2023. Komite Pencegahan dan Pengendalian Infeksi Program Pengendalian Resistensi Antimikroba RSUP Dr. Sardjito Yogyakarta, Yogyakarta, hal. 1-274.
- Meini, S., Tascini, C., Cei, M., Sozio, E., & Rossolini, G.M. (2019). AmpC β -lactamase-producing *Enterobacteriales*: what a clinician should know. *Infection* 47 : 363–375.
- Mirzaei, B., Babaei, R., Bazgir, Z.N., Goli, H.R., Keshavarzi, S., & Amiri, E. (2021). Prevalence of *Enterobacteriaceae spp.* and its multidrug-resistant rates in clinical isolates: A two-center cross-sectional study. *Mol Biol Rep* 48 : 665–675.
- Najjuka, C.F., Kateete, D.P., Lodiongo, D.K., Mambo, O., Mocktar, C., Kayondo, W., *et al.* (2020). Prevalence of plasmid-mediated AmpC beta-lactamases in *Enterobacteriaceae* isolated from urban and rural folks in Uganda. *AAS Open Res* 3 : 62.
- Navon-Venezia, S., Kondratyeva, K., & Carattoli, A. (2017). *Klebsiella pneumoniae*: a major worldwide source and shuttle for antibiotic resistance. *FEMS Microbiol Rev* 41 : 252–275.
- Oliveira, J., & Reygaert, W.C. (2025). Gram-Negative Bacteria, in: *StatPearls*. Treasure Island (FL) : StatPearls Publishing.

- O'Neill, J. (2016). Tackling drug-resistant infections globally: final report and recommendations. London : Wellcome Trust.
- Paczosa, M.K., & Mecsas, J. (2016). *Klebsiella pneumoniae*: Going on the Offense with a Strong Defense. *Microbiol Mol Biol Rev* 80 : 629–661.
- Park, Y.S., Yoo, S., Seo, M.-R., Kim, J.Y., Cho, Y.K., & Pai, H. (2009). Risk factors and clinical features of infections caused by plasmid-mediated AmpC β -lactamase-producing *Enterobacteriaceae*. *Int J Antimicrob Agents* 34 : 38–43.
- Pascual, V., Ortiz, G., Simo, M., Alonso, N., Garcia, M.C., Xercavins, M., *et al.* (2015). Epidemiology and risk factors for infections due to AmpC - lactamase-producing *Escherichia coli*. *J Antimicrob Chemother* 70 : 899–904.
- Paterson, D.L. (2006). Resistance in Gram-Negative Bacteria: *Enterobacteriaceae*. *Am J Med* 119 : S20–S28.
- Permatasari, D.A., Witaningrum, A.M., Wibisono, F.J., & Effendi, M.H. (2020). Detection and prevalence of multidrug-resistant *Klebsiella pneumoniae* strains isolated from poultry farms in Blitar, Indonesia. *Biodiversitas* 21 : 4642–4647.
- Priyaka, I.G.N.K., Tarini, N.M.A., & Fatmawati, N.N.D. (2019). Deteksi Molekuler Gen AmpC pada Isolat Klinis *Klebsiella pneumoniae* Penghasil ESBL di RSUP Sanglah Denpasar. *Jurnal Medika Udayana* 8 : 1–5.
- Riedel, S., Hobden, J.A., Miller, S., Morse, S.A., Mietzner, T.A., Detrick, B., *et al.* (2019). Enteric Gram-negative Rods (*Enterobacteriaceae*), in: Riedel, S., Morse, S.A., Mietzner, S.A., Miller, S (Ed.) *Jawetz, Melnick, & Adelberg's Medical Microbiology*. Mc Graw Hill Lange, New York, hal. 235–252.
- Shagufta, R., Fomda, B., Gulnaz, B., Lubna, S., Jan, A., Mohd, S., *et al.* (2017). Prevalence of AmpC Beta-lactamase in Gram Negative Bacilli by Different Phenotypic Methods in a Tertiary Care Institute in Kashmir. *British Journal of Medicine and Medical Research* 19 : 1–9.
- Sood, R., Walo, C., Burton, R., Khalife, M., Dicko, A., & Mangana, F. (2023). Spontaneous nosocomial *Proteus mirabilis* meningitis in a Human Immunodeficiency Virus (HIV)-infected adult patient: a case report. *J Med Case Reports* 17 : 1–7.
- Tamma, P.D., Aitken, S.L., Bonomo, R.A., Mathers, A.J., Van Duin, D., & Clancy, C.J. (2023). Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. *Clin Infect Dis* 1–53.
- Tamma, P.D., Doi, Y., Bonomo, R.A., Johnson, J.K., Simner, P.J., Antibacterial Resistance Leadership Group, *et al.* (2019). A Primer on AmpC β -Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. *Clin Infect Dis* 69 : 1446–1455.
- Tebano, G., Zaghi, I., Cricca, M., & Cristini, F. (2024). Antibiotic Treatment of Infections Caused by AmpC-Producing *Enterobacterales*. *Pharmacy* 12 : 1–17.
- Tekele, S.G., Teklu, D.S., Tullu, K.D., Birru, S.K., & Legese, M.H. (2020). Extended-spectrum Beta-lactamase and AmpC beta-lactamases producing

- gram negative bacilli isolated from clinical specimens at International Clinical Laboratories, Addis Ababa, Ethiopia. *PLOS ONE* 15 : e0241984.
- Tewari, R., Mitra, S.D., Ganaie, F., Venugopal, N., Das, S., Shome, R., *et al.* (2018). Prevalence of extended spectrum β -lactamase, AmpC β -lactamase and metallo β -lactamase mediated resistance in *Escherichia coli* from diagnostic and tertiary healthcare centers in south Bangalore, India. *Int J Res Med Sci* 6 : 1308–1313.
- Tille, P.M. (2017). Enterobacteriaceae, in: Tille, P.M (Ed.) *Bailey & Scott's Diagnostic Microbiology*. Elsevier, St. Louis Missouri, hal. 239–356.
- Toleman, M.A., Bennett, P.M., & Walsh, T.R. (2006). IS *CR* Elements: Novel Gene-Capturing Systems of the 21st Century? *Microbiol Mol Biol Rev* 70 : 296–316.
- Woodford, N., Turton, J.F., & Livermore, D.M. (2011). Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. *FEMS Microbiol Rev* 35 : 736–755.
- Yong, D., Lim, Y.S., Roh, K.H., Choi, Y.S., Park, D.-Y., Yum, J.H., *et al.* (2006). The first detection of CTX-M-14 extended-spectrum β -lactamase among diverse β -lactamase-producing *Proteus mirabilis* clinical isolates. *Diagn Microbiol Infect Dis* 54 : 237–239.
- Zamorano, L., Miró, E., Juan, C., Gómez, L., Bou, G., González-López, J.J., *et al.* (2015). Mobile Genetic Elements Related to the Diffusion of Plasmid-Mediated AmpC β -Lactamases or Carbapenemases from *Enterobacteriaceae*: Findings from a Multicenter Study in Spain. *Antimicrob Agents Chemother* 59 : 5260–5266.
- Zerr, D.M., Miles-Jay, A., Kronman, M.P., Zhou, C., Adler, A.L., Haaland, W., *et al.* (2016). Previous Antibiotic Exposure Increases Risk of Infection with Extended-Spectrum- β -Lactamase- and AmpC-Producing *Escherichia coli* and *Klebsiella pneumoniae* in Pediatric Patients. *Antimicrob Agents Chemother* 60 : 4237–4243.
- Zhou, Q., Tang, M., Zhang, X., Lu, J., Tang, X., & Gao, Y. (2022). Detection of AmpC β -lactamases in gram-negative bacteria. *Heliyon* 8 : 1–7.
- Zhu, Y., Huang, W.E., & Yang, Q. (2022). Clinical Perspective of Antimicrobial Resistance in Bacteria. *Infect Drug Resist* Volume 15 : 735–746.